BACPLEX TECHNOLOGIES PRIVATE LIMITED

In their own words

The World Health Organization (WHO) estimates that multi-drug resistance (MDR) bacterial infections result in approximately 700,000 deaths worldwide each year. As per another report by WHO, deaths by MDR bacterial infections will surpass cancer-related mortalities with up to 10 million deaths annually. Hence, the goal of our startup company is to provide an innovative, rapid, cost-effective, processing-free, one-step, fully automated, quantitative, and effective “Sample-to-answer” platform for the detection and management of infections caused by MDR bacteria, ultimately improving patient outcomes and reducing the burden of infectious diseases on society. Our innovative sample-to-answer platform for bacterial diagnostics will play a crucial role in improving the speed, accuracy, and accessibility of bacterial infection detection in a cost-effective manner which is not possible at this moment. This innovative sample-to-answer platform for bacterial diagnostics holds significant potential in revolutionizing the field of bacterial infection detection by providing rapid, accurate, and accessible diagnostic solutions. It will enhance clinical decision-making, improve patient outcomes, and contribute to the effective management of bacterial infections at both individual and population levels.

Written by the company on its public Startup India profile. Not verified by us.